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Introduction
Pregnancy is one of the physiological conditions that 
requires lengthy and significant restructuring of many sys-
tems of an organism to properly maintain homeostasis.1,2 
Therefore, studying changes in the functions of the cardio-
vascular system (CVS) during pregnancy and the factors 
responsible for these changes, is an important medical chal-
lenge. These functional changes may result in an increased 
load on the cardiovascular system of a woman.3 Impairments 
of the cardiovascular system during pregnancy may cause 
preeclampsia4,5 and, thereby, lead to chronic intrauterine 
hypoxia and placental failure.6
The renin-angiotensin-aldosterone system and, in par-
ticular, angiotensin-converting enzyme (ACE) is known to 
play an important regulatory role in the function of the 
CVS. The enzyme hydrolyses angiotensin I into angioten-
sin II, a powerful vasoconstrictor.7 Several polymorphisms 
of the ACE gene have been studied with respect to 
the association with CVS functioning under normal and 
diseased conditions.8–10 One of these polymorphisms is an 
insertion-deletion (I/D) of the 287-bp Alu repetitive ele-
ment in intron 16 of the gene.11 The polymorphism does not 
affect the protein structure but apparently influences 
expression of this gene.
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Several studies reported that blood ACE levels in healthy 
individuals with the DD genotype were twice as high as 
those in the II homozygotes, with the heterozygotes having 
an intermediate value.11–13 The studies reporting the asso-
ciation of the I/D polymorphism of the ACE gene with the 
blood pressure (BP) level in pregnant women are contradic-
tory. This prompts further research on the role of the I/D 
polymorphism of ACE gene in the regulation of BP during 
pregnancy.
Materials and methods
Study subjects
The study population included 591 unrelated women of 
Russian descent living in Central Russia (Belgorod region). 
The age of the women varied from 20–43 years (mean age 
27.98±4.50 years). The study was approved by the Regional 
Ethics Committee at Belgorod State University. All women 
signed an informed consent form prior to the recruitment 
for this study.
Clinical and laboratory examinations of women were 
conducted at the Perinatal Center (Division of Pathological 
Pregnancy) of the Belgorod Regional Clinical Hospital. 
The criteria for inclusion in the study group were (a) 
Russian nationality; (b) pregnancy at 37–40 weeks of ges-
tation; and (с) signed informed consent for the study. 
Pregnant women with diabetes mellitus, hepatic or renal 
failure, and those at a gestation <37 weeks and >40 weeks 
were excluded from the study. A general outline is shown in 
Figure 1. BP level was measured three times by experi-
enced obstetricians according to the American Heart 
Association recommendations.14 The measurements were 
done in the morning (between 0700–0900 hours) and even-
ing (between 1900–2100 hours). The data on BP level 
before pregnancy were obtained from the medical records 
of each woman. The mean arterial pressure (MAP, mm Hg) 
was calculated as follows:
MAP=(SBP+2DBP)/3 where SBP is systolic blood 
pressure and DBP is diastolic blood pressure.15
All study participants were divided into three groups 
depending on the BP level at the end of pregnancy. The 
groups included normotensive women (SBP from 90–140 
mm Hg and/or DBP from 60–90 mm Hg), hypotensive 
women (SBP<90 mm Hg and/or DBP<60 mm Hg), and 
hypertensive women (SBP>140 mm Hg and/or DBP>90 
mm Hg).16
DNA extraction and genotyping
Venous blood (8–9 ml) was drawn from the ulnar vein of 
each woman. Genomic DNA was isolated using the 
method proposed Miller and et al.17 Genotyping of the 
insertion-deletion polymorphism (rs4646994) of the ACE 
gene was performed using a polymerase chain reaction 
(PCR) and amplified fragment length polymorphism 
(AFLP) assay according to the protocol described 
elsewhere.18
Statistical analysis
Allele frequencies of the ACE gene polymorphism were 
estimated by the gene counting method, and the chi-squire 
test was used to identify significant departure from Hardy–
Weinberg equilibrium (HWE). The distribution of allele 
and genotype frequencies between the study groups was 
compared by the chi-squire test for 2×2 contingency tables. 
The p-values were adjusted for multiple testing using the 
Bonferroni correction (pcor). The distribution of the quanti-
tative traits such as SBP, DBP, MAP and pulse pressure (the 
pressure difference between the systolic and diastolic pres-
sures) before and at the end of pregnancy were analyzed by 
the Shapiro-Wilk’s test.19 Because the values of the quanti-
tative traits did not follow the normal distribution, median 
(Me) and interquartile range (Q25–Q75) were used for their 
description and intergroup comparisons were done using 
the Mann-Whitney test.20 Linear regression analysis was 
used to estimate the impact of age, weight, and ACE geno-
types on the BP parameters in women. All statistical analy-
ses were performed using STATISTICA for Windows v. 6.0 
(StatSoft, USA).
Results
The biomedical and clinical characteristics of the study 
women are shown in Table 1. As can be seen from Table 1, the 
prevalence of hypertension among women before and at the 
end of pregnancy was 10.3% and 51.7%, respectively. The 
prevalence of hypotension dropped from 19.1% prior to preg-
nancy to 4.1% at the end of pregnancy. Moreover the values 
of BP increased significantly in women to the end of preg-
nancy in comparison with women prior to pregnancy. Obesity 
was found in 20.6% the study women. Moreover 15.1% of 
women had excessive body weight, whereas 8.1% of women 
had decreased body weight. The study group also comprised 
7.8% of women who had other extragenital pathology.
The observed ACE genotype frequencies in the study par-
ticipants were in Hardy-Weinberg equilibrium. The frequency 
of allele D in the entire group (n=591) was 0.533. Frequency 
of genotypes II, ID, and DD were 19.97% (n=118), 53.47% 
(n =316), and 26.56% (n =157), respectively, which is con-
sistent with data reported in other European populations.21 No 
statistically significant differences in the distribution of the 
ACE genotypes prior to pregnancy were observed between 
the three study groups (Table 2).
Friedman′s ANOVA test allowed us to reveal that the 
BP parameters increased significantly by the end of preg-
nancy in comparison with those prior to pregnancy, with 
 at Belgorod State University on November 10, 2015jra.sagepub.comDownloaded from 
Reshetnikov et al. 625
most increased BP level in carriers of genotype DD. 
However, as can be seen from Table 2, the values of the 
systolic and mean BP during pregnancy were the lowest in 
women with the II genotype and the highest in women 
with the DD genotype. At 37–40 weeks of gestation, 
women with genotypes DD and ID had greater values of 
SBP, DBP and average BP as compared to those with 
genotype II. Furthermore, the frequency of allele D was 
the highest in the group of women with hypertension at the 
end of pregnancy (56.6%) followed by the subjects with 
normotension (50.7%) and hypotension (35.0%) (the data 
are shown in Figure 2). Accordingly, the largest number of 
individuals with genotype DD and the lowest one with 
genotype II were observed in the hypertensive women 
Figure 1. The general outline of the investigation.
ACE: angiotensin-converting enzyme; I/D: insertion-deletion.
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(29.5% and 16.4%, p=0.01, pcor=0.03), while the opposite 
pattern of the genotype distribution was seen in the hypo-
tensive group (6.7% and 36.6%, p=0.02, pcor=0.06) (Figure 
3). None of the study groups (normotensive, hypotensive 
or hypertensive women) showed statistically significant 
differences in the parameters of BP between the carriers of 
the ACE genotypes among women before and during a 
pregnancy (Table 3).
Linear regression analysis observed the impact of cur-
rent age (t=2.9, p=0.004), weight (t=8.2, p<0.0001) and the 
ACE polymorphism (t=–3.8, p=0.0002) on SBP at the end 
of pregnancy (R2=15.33%). In addition, the DBP depended 
(R2=10.9%) on the same factors such as current age (t=2.3, 
p=0.02), weight (t=6.7, p<0.0001) and the ACE genotypes 
(t=–3.5, p=0.0006). The impact of the same factors was 
seen with respect to the pulse pressure of pregnant women.
Discussion
The results of the present study suggest that the I/D poly-
morphism of the ACE gene is associated with the level of 
arterial BP at the later stage of pregnancy (37–40 weeks) in 
women. Allele D confers higher BP, whereas allele I is 
associated with lower BP. The observed association 
between the I/D polymorphism of the ACE gene and level 
of BP in women at the end of pregnancy is supported by the 
data about the physiological role of this enzyme. It has been 
recently reported that healthy individuals possessing the D 
allele of the ACE gene had significantly higher levels of the 
circulating enzyme in blood than those possessing the 
homozygous II genotype, while the heterozygotes had the 
intermediate levels.11–13 The ACE enzyme participates in 
the synthesis of angiotensin II, which has a strong vasocon-
strictor effect.22 Therefore, individuals with the highly 
expressed DD genotype have a higher vascular tone and BP 
level.23 Furthermore, under normal conditions, concentra-
tion of the ACE in plasma of pregnant women constantly 
increases until the third trimester. Notably, women with 
genotype DD ACE have the maximum concentration of the 
enzyme as compared to those with genotypes ID and II,11,12 
and in turn, this results in higher BP at the end of 
pregnancy.
Ample evidence exists about association of the I/D ACE 
polymorphism with various cardiovascular disorders such 
as essential hypertension,24,25 coronary artery disease,26,27 
myocardial infarction,28 and myocardial hypertrophy.29 It 
should be noted that the renin-angiotensin-aldosterone sys-
tem may be involved in the development of both insulin 
resistance and gestational diabetes mellitus.30 The increased 
levels of ACE in plasma accounted for by the DD geno-
type11 may be responsible for the increasing levels of aldos-
terone and thereby lead to insulin resistance and gestational 
diabetes.
The literature data on association between the I/D poly-
morphism of the ACE gene and hypertension during preg-
nancy are contradictory. In Table 4, we summarize several 
genetic studies which investigated the association of I/D 
polymorphism of the ACE gene and BP level during preg-
nancy. In particular, a higher frequency of allele D and 
genotype DD was reported among patients with pregnancy-
induced hypertension (PIH) in the Chinese population.31,32 
One of the studies32 has found the association of genotype 
DD with higher concentrations of plasma angiotensin II in 
pregnant women with hypertension, as compared to healthy 
women. Similar results were obtained in the Indian sample 
consisting of 50 pregnant women with PIH and 50 pregnant 
women with normotension.33 The authors reported the 
association of genotype DD with PIH, although they did 
not find any association of the I/D polymorphism with 
either plasma ACE levels or hypertension.33
The study conducted on the Arabian population has 
found a relationship between the genotype DD and hyper-
tension in pregnant women with preeclampsia.34 However, 
contradictory results have been obtained in a number of 
studies conducted in Chinese, Indian, African and Italian 
populations.35–38 In particular, in the sample of 104 preg-
nant women from Northern India, no association of either 
Table 1. The biomedical and clinical characteristics of the study 
women. 
Variables Value
Number 591
Age, years 26.0 (24.0–31.0)
Height, m 1.65 (1.62–1.68)
Before pregnancy, Me (Q25–Q75)
Weight, kg 70.0 (59.0–81.7)
BMI, kg/m2 23.0 (21.2–26.9)
SBP, mmHg 110.0 (110.0–120.0)
DBP, mmHg 70.0 (70.0–80.0)
PBP, mmHg 40.0 (40.0–45.0)
MAP, mmHg 83.3 (81.7–93.3)
Hypotension 113 (19.1%)
Normotension 417 (70.6%)
Hypertension 61 (10.3%)
During pregnancy (37–40 weeks term), Me (Q25–Q75)
Weight, kg 79.3 (71.6–90.4)
BMI, kg/m2 29.2 (26.4–33.8)
SBP, mm Hg 130.0 (115.0–145.0)
DBP, mm Hg 80.0 (75.0–90.0)
PBP, mm Hg 50.0 (40.0–55.0)
MAP, mm Hg 100.0 (88.3–110.0)
∆MAP, mm Hg 13.3 (3.3–23.3)
∆SBP, mm Hg 20.0 (10.0–30.0)
∆DBP, mm Hg 10.0 (0.0–20.0)
Hypotension 24 (4.1%)
Normotension 261 (44.2%)
Hypertension 306 (51.7%)
BMI: body mass index; DBP: diastolic blood pressure ∆DBP: change of 
diastolic blood pressure; ∆MAP: change of mean arterial pressure; ∆SBP: 
change of systolic blood pressure; MAP: mean arterial pressure; Me: 
median; PBP: pulse blood pressure; Q25–Q75: interquartile range; SBP: 
systolic blood pressure.
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Table 3. Association analysis of the angiotensin-converting enzyme (ACE) insertion-deletion (I/D) polymorphism with blood 
pressure parameters in hypotensive, normotensive and hypertensive groups of women.
Values of blood 
pressure
Genotypes p
 DD ID II  
 1 2 3 1–2 2–3 1–3
Hypotension
 DD (n=30) ID (n=57) II (n=26)  
SBP, mm Hg
 
 
Before pregnancy 90.0(90.0–100.0) 90.0 (90.0–100.0) 90.0 (90.0–105.0) 0.5 0.3 0.8
DD (n=3) ID (n=14) II (n=7)  
During pregnancy 
(37–40 weeks term)
90.0 (90.0–90.0) 100.0 (90.0–100.0) 90.0 (90.0–100.0) 0.9 0.3 0.9
DBP, mm Hg Before pregnancy 60.0 (60.0–60.0) 60.0 (60.0–60.0) 60.0 (60.0–60.0) 0.4 0.98 0.5
Figure 2. Distribution of the alleles of the angiotensin-converting enzyme (ACE) insertion-deletion (I/D) polymorphism in the 
groups of pregnant (37–40 weeks term) women with different blood pressure status.
Figure 3. Distribution of the genotypes of the angiotensin-converting enzyme (ACE) insertion-deletion (I/D) polymorphism in the 
groups of pregnant (37–40 weeks term) women with different blood pressure status.
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Values of blood 
pressure
Genotypes p
 DD ID II  
 1 2 3 1–2 2–3 1–3
 During pregnancy 
(37–40 weeks term)
60.0 (60.0–60.0) 60.0 (60.0–60.0) 60.0 (60.0–60.0) 0.8 0.5 0.9
PBP, mm Hg Before pregnancy 35.0 (30.0–40.0) 30.0 (30.0–40.0) 30.0 (30.0–45.0) 0.2 0.3 0.98
 During pregnancy 
(37–40 weeks term)
30.0 (30.0–30.0) 40.0 (30.0–40.0) 30.0 (30.0–40.0) 0.8 0.2 0.9
MAP, mm Hg Before pregnancy 70.0 (70.0–73.3) 70.0 (70.0–73.3) 70.0 (70.0–75.0) 0.7 0.7 0.5
 During pregnancy 
(37–40 weeks term)
70.0 (70.0–70.0) 73.3 (70.0–73.3) 73.3 (70.0–73.3) 0.7 0.9 0.8
∆MAP, mm Hg 0.0 (0.0–0.0) 3.3 (2.5–5.8) 3.3 (1.7–6.7) 0.7 0.8 0.8
∆SBP, mm Hg 0.0 (0.0–0.0) 10.0 (7.5–17.5) 5.0 (0.0–10.0) 0.8 0.3 0.9
∆DBP, mm Hg 0.0 (0.0–0.0) 0.0 (0.0–0.0) 0.0 (0.0–5.0) 0.8 0.3 0.7
Normotension  
 DD (n=110) ID (n=226) II (n=81)  
SBP, mm Hg Before pregnancy 110.0 (110.0–120.0) 110.0 (110.0–120.0) 110.0 (110.0–115.0) 0.8 0.1 0.3
 DD (n=66) ID (n=131) II (n=64)  
 During pregnancy 
(37–40 weeks term)
120.0 (110.0–130.0) 115.0 (110.0–120.0) 115.0 (110.0–120.0) 0.1 0.8 0.1
DBP, mm Hg Before pregnancy 70.0 (70.0–80.0) 70.0 (70.0–75.0) 70.0 (70.0–70.0) 0.5 0.5 0.2
 During pregnancy 
(37–40 weeks term)
75.0 (70.0–80.0) 70.0 (70.0–80.0) 75.0 (70.0–80.0) 0.1 0.5 0.4
PBP, mm Hg Before Pregnancy 40.0 (40.0–40.0) 40.0 (40.0–45.0) 40.0 (40.0–40.0) 0.4 0.3 0.8
 During pregnancy 
(37–40 weeks term)
40.0 (40.0–50.0) 40.0 (40.0–50.0) 40.0 (35.0–50.0) 0.4 0.4 0.2
MAP, mm Hg Before pregnancy 83.3 (83.3–90.0) 83.3 (83.3–86.7) 83.3 (83.3–86.7) 0.7 0.2 0.2
 During pregnancy 
(37–40 weeks term)
88.3 (83.3–96.7) 86.7 (83.3–93.3) 86.7 (83.3–93.3) 0.1 0.8 0.1
∆MAP, mm Hg 5.0 (3.3–13.3) 4.2 (1.7–10.0) 6.7 (3.3–11.7) 0.2 0.1 0.99
∆SBP, mm Hg 10.0 (0.0–20.0) 5.0 (0.0–10.0) 10.0 (5.0–10.0) 0.2 0.7 0.5
∆DBP, mm Hg 5.0 (0.0–10.0) 5.0 (0.0–10.0) 10.0 (0.0–10.0) 0.2 0.1 0.6
Hypertension  
 DD (n=17) ID (n=33) II (n=11)  
SBP, mm Hg Before pregnancy 140.0 (135.0–140.0) 140.0 (140.0–150.0) 135.0 (135.0–140.0) 0.1 0.1 0.1
 DD (n=88) ID (n=171) II (n=47)  
 During pregnancy 
(37–40 weeks term)
145.0 (140.0–160.0) 140.0 (140.0–150.0) 140.0 (140.0–150.0) 0.4 0.3 0.1
DBP, mm Hg Before pregnancy 90.0 (90.0–95.0) 90.0 (90.0–95.0) 90.0 (90.0–90.0) 0.9 0.6 0.5
 During pregnancy 
(37–40 weeks term)
90.0 (90.0–100.0) 90.0 (90.0–100.0) 90.0 (90.0–97.5) 0.7 0.1 0.1
PBP, mm Hg Before pregnancy 50.0 (45.0–60.0) 50.0 (50.0–60.0) 45.0 (45.0–47.5) 0.2 0.1 0.4
 During pregnancy 
(37–40 weeks term)
55.0 (50.0–60.0) 50.0 (50.0–60.0) 50.0 (50.0–60.0) 0.4 0.96 0.5
MAP, mm Hg Before pregnancy 106.7 (105.0–108.3) 106.7 (106.7–110.0) 105.0 (104.2–105.8) 0.3 0.1 0.3
 During pregnancy 
(37–40 weeks term)
110.0 (105.0–118.3) 108.3 (105.0–116.7) 106.7 (103.3–115.0) 0.6 0.1 0.1
∆MAP, mm Hg 23.3 (16.7–31.7) 21.7 (16.7–30.0) 20.0 (15.8–25.0) 0.2 0.6 0.1
∆SBP,  
mm Hg 30.0 (20.0–40.0) 30.0 (20.0–40.0) 30.0 (20.0–30.0) 0.1 0.8 0.2
∆DBP, mm Hg 20.0 (10.0–30.0) 20.0 (10.0–30.0) 20.0 (10.0–25.0) 0.3 0.5 0.2
SBP: systolic blood pressure; DBP: diastolic blood pressure; p: value for the Mann-Whitney test; PBP: pulse blood pressure; MAP: mean arterial pres-
sure. The value of blood pressure level is expressed as median (Me) interquartile range (Q25–Q75).
Table 3. (Continued)
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allele D or genotype DD with PIH was observed despite 
the higher blood ACE levels in the carriers of DD genotype 
as compared to the carriers of the ID and II genotypes.36 
Similar results were reported for the Chinese, Africans 
and Italians.35,37–39 A large study (more than 1000 
Caucasian women) conducted by Pfab with coworkers did 
not reveal the association of I/D polymorphism of the 
ACE gene with BP level during a pregnancy.40 Meantime, 
a meta-analysis of more than 50 studies showed a signifi-
cant association of the I/D polymorphism with PIH and 
preeclampsia in Chinese,41,42 and in Asians and 
Caucasians.43 The observed inconsistency in the above 
results may be explained by inter-population and intereth-
nic differences in the distribution of the I/D polymor-
phism: allele D is predominant in Caucasians from 
Europe, Australia and the USA, whereas allele I is more 
prevalent among Chinese and Indians.44–47 Therefore, this 
feature may explain the different clinical importance of 
the polymorphism for PIH in populations of the world. 
The existing inconsistency in the genetic studies warrants 
further research into the role of the ACE gene in the regu-
lation of BP and the development of PIH.
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